Optimization strategies and advances in the research and development of AAV-based gene therapy to deliver large transgenes

Abstract

Adeno-associated virus (AAV)-based therapies are recognized as one of the most potent next-generation treatments for inherited and genetic diseases. However, several biological and technological aspects of AAV vectors remain a critical issue for their widespread clinical application. Among them, the limited capacity of the AAV genome significantly hinders the development of AAV-based gene therapy. In this context, genetically modified transgenes compatible with AAV are opening up new opportunities for unlimited gene therapies for many genetic disorders. Recent advances in de novo protein design and remodelling are paving the way for new, more efficient and targeted gene therapeutics. Using computational and genetic tools, AAV expression cassette and transgenic DNA can be split, miniaturized, shuffled or created from scratch to mediate efficient gene transfer into targeted cells. In this review, we highlight recent advances in AAV-based gene therapy with a focus on its use in translational research. We summarize recent research and development in gene therapy, with an emphasis on large transgenes (>4.8 kb) and optimizing strategies applied by biomedical companies in the research pipeline. We critically discuss the prospects for AAV-based treatment and some emerging challenges. We anticipate that the continued development of novel computational tools will lead to rapid advances in basic gene therapy research and translational studies.

Keywords

exons remodelling / gene editing / gene therapies / inteins / minigenes / protein design / rare diseases / trans-splicing / viral deliveries / viral vectors

References

[1] Pupo A, Fernández A, Low SH, François A, Suárez-Amarán L, Samulski RJ. AAV vectors: the rubik's cube of human gene therapy. Mol Ther. 2022;30:3515-3541.

[2] Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther—Methods Clin Dev. 2018;8:87-104.

[3] Bulcha JT, Wang Yi, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduction Targeted Ther. 2021;6:1-24.

[4] Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541-555.

[5] Ghosh S, Brown AM, Jenkins C, Campbell K. Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges. Appl Biosaf. 2020;25:7-18.

[6] De Haan P, Van Diemen FR, Toscano MG. Viral gene delivery vectors: the next generation medicines for immune-related diseases. Hum Vaccin Immunother. 2021;17:14-21.

[7] Zu H, Gao D. Non-viral vectors in gene therapy: recent development, challenges, and prospects. AAPS J. 2021;23:1-12.

[8] Technological aspects of manufacturing and analytical control of biological nanoparticles. Biotechnol Adv. 2023;64:108122.

[9] Kulkarni JA, Witzigmann D, Thomson SB, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16:630-643.

[10] Durymanov M, Reineke J. Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers. Front Pharmacol. 2018;9:398662.

[11] Gantenbein B, Tang S, Guerrero J, et al. Non-viral gene delivery methods for bone and joints. Front Bioeng Biotechnol. 2020;8:598466.

[12] Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358-378.

[13] Dong J-Y, Fan P-D, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther. 1996;7:2101-2112.

[14] Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A. 2010;107:10220-10225.

[15] Brister JR, Muzyczka N. Rep-mediated nicking of the adeno-associated virus origin requires two biochemical activities, DNA helicase activity and transesterification. J Virol. 1999;73:9325-9336.

[16] Issa SS, Shaimardanova AA, Solovyeva VV, Rizvanov AA. Various AAV serotypes and their applications in gene therapy: an overview. Cells. 2023;12:785.

[17] Hauck B, Chen L, Xiao W. Generation and characterization of chimeric recombinant AAV vectors. Mol Ther. 2003;7:419-425.

[18] Landegger LD, Pan B, Askew C, et al. A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear. Nat Biotechnol. 2017;35:280-284.

[19] Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 1991;10:3941-3950.

[20] Duan D. Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy. Mol Ther. 2018;26:2337-2356.

[21] Hicks MJ, Rosenberg JB, De BP, et al. AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Sci Transl Med. 2012;4:140ra87.

[22] Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101:2963-2972.

[23] Termini JM, Martinez-Navio JM, Gao G, Fuchs SP, Desrosiers RC. Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity. Mol. Ther—Methods Clin Dev. 2021;20:204-217.

[24] Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother. 2022;153:113324.

[25] Yang Q, Tang Y, Imbrogno K, et al. AAV-based shRNA silencing of NF-κB ameliorates muscle pathologies in mdx mice. Gene Ther. 2012;19:1196-1204.

[26] Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene. 2003;22:5712-5715.

[27] Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell. 2020;181:136-150.

[28] Davis JR, Wang X, Witte IP, et al. Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat Biomed Eng. 2022;6:1272-1283.

[29] Aslesh T, Yokota T. Restoring SMN expression: an overview of the therapeutic developments for the treatment of spinal muscular atrophy. Cells. 2022;11:417.

[30] Peccate C, Mollard A, Le Hir M, et al. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. Hum Mol Genet. 2016;25:3555-3563.

[31]

[32] European Medicines Agency. First gene therapy to treat haemophilia B. European Medicines Agency; 2022.

[33] Center for Biologics Evaluation & Research. Approved cellular and gene therapy products. U.S. Food and Drug Administration; 2023.

[34] Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest. 2008;118:1955-1964.

[35] Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010;18:80-86.

[36] Dong B, Nakai H, Xiao W. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther. 2010;18:87-92.

[37] Shao L, Shen W, Wang S, Qiu J. Recent advances in molecular biology of human bocavirus 1 and its applications. Front Microbiol. 2021;12:696604.

[38] Qiu J, Söderlund-Venermo M, Young NS. Human parvoviruses. Clin Microbiol Rev. 2017;30:43-113.

[39] Molecular dynamics simulation for rational protein engineering: present and future prospectus. J Mol Graph Model. 2018;84:43-53.

[40] Tertrais M, Bouleau Y, Emptoz A, et al. Viral transfer of mini-otoferlins partially restores the fast component of exocytosis and uncovers ultrafast endocytosis in auditory hair cells of otoferlin knock-out mice. J Neurosci. 2019;39:3394-3411.

[41] Ivanchenko MV, Hathaway DM, Klein AJ, et al. Mini-PCDH15 gene therapy rescues hearing in a mouse model of usher syndrome type 1F. Nat Commun. 2023;14:2400.

[42] Wang W, Vandenberghe LH. Miniaturization of usher syndrome type 2A gene for AAV mediated gene therapy. Invest Ophthalmol Vis Sci. 2021;62:1194-1194.

[43] Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919-928.

[44] Rando TA. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 2001;24:1575-1594.

[45] Van Deutekom JCT, Van Ommen G-JB. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet. 2003;4:774-783.

[46] Birch SM, Lawlor MW, Conlon TJ, et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci Transl Med. 2023;15:eabo1815.

[47] Manini A, Abati E, Nuredini A, Corti S, Comi GP. Adeno-associated virus (AAV)-mediated gene therapy for Duchenne muscular dystrophy: the issue of transgene persistence. Front Neurol. 2021;12:814174.

[48] Lenting PJ, Van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92:3983-3996.

[49] Hu Z, Li Z, Wu Y, et al. Targeted B-domain deletion restores F8 function in human endothelial cells and mice. Signal Transduction Targeted Ther. 2022;7:1-3.

[50] Domenger C, Grimm D. Next-generation AAV vectors-do not judge a virus (only) by its cover. Hum Mol Genet. 2019;28:R3-R14.

[51] Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21:255-272.

[52] Suoranta T, Laham-Karam N, Ylä-Herttuala S. Strategies to improve safety profile of AAV vectors. Front Mol Med. 2022;2:1054069.

[53] Becker J, Fakhiri J, Grimm D. Fantastic AAV gene therapy vectors and how to find them-random diversification, rational design and machine learning. Pathogens. 2022;11:756.

[54] Nieuwenhuis B, Haenzi B, Hilton S, et al. Optimization of adeno-associated viral vector-mediated transduction of the corticospinal tract: comparison of four promoters. Gene Ther. 2021;28:56-74.

[55] Nieuwenhuis B, Laperrousaz E, Tribble JR, et al. Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters. Gene Ther. 2023;30:503-519.

[56] Skopenkova VV, Egorova TV, Bardina MV. Muscle-specific promoters for gene therapy. Acta Naturae. 2021;13:47-58.

[57] Soroka AB, Feoktistova SG, Mityaeva ON, Volchkov PY. Gene therapy approaches for the treatment of hemophilia B. Int J Mol Sci. 2023;24:10766.

[58] ROCTAVIANTM (valoctocogene roxaparvovec-rvox). BioMarin

[59] Chai S, Wakefield L, Norgard M, et al. Strong ubiquitous micro-promoters for recombinant adeno-associated viral vectors. Mol Ther Methods Clin Dev. 2023;29:504-512.

[60] Yan Z, Zak R, Zhang Y, Engelhardt JF. Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J Virol. 2005;79:364-379.

[61] Earley LF, Conatser LM, Lue VM, et al. Adeno-associated virus serotype-specific inverted terminal repeat sequence role in vector transgene expression. Hum Gene Ther. 2020;31:151-162.

[62] Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol. 1999;73:861-861.

[63] Mccarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 2003;10:2112-2118.

[64] Mccarty Dm, Monahan Pe, Samulski Rj. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8:1248-1254.

[65] Wu J, Zhao W, Zhong Li, et al. Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther. 2007;18:171-182.

[66] Mccarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther. 2008;16:1648-1656.

[67] Savy A, Dickx Y, Nauwynck L, Bonnin D, Merten O-W, Galibert L. Impact of inverted terminal repeat integrity on rAAV8 production using the baculovirus/Sf9 cells system. Hum Gene Ther Methods. 2017;28:277-289.

[68] Ryan JH, Zolotukhin S, Muzyczka N. Sequence requirements for binding of Rep68 to the adeno-associated virus terminal repeats. J Virol. 1996;70:1542-1553.

[69] Shitik EM, Shalik IK, Yudkin DV. AAV- based vector improvements unrelated to capsid protein modification. Front Med. 2023;10:1106085.

[70] Liu Y, Joo K-I, Wang P. Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther. 2013;20:308-317.

[71] Hanlon KS, Meltzer JC, Buzhdygan T, et al. Selection of an efficient AAV vector for robust CNS transgene expression. Mol Ther Methods Clin Dev. 2019;15:320-332.

[72] Choi J-H, Yu N-K, Baek Gi-C, et al. Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons. Mol Brain. 2014;7:17.

[73] Fuentes CM, Schaffer DV. Adeno-associated virus-mediated delivery of CRISPR-Cas9 for genome editing in the central nervous system. Curr Opin Biomed Eng. 2018;7:33-41.

[74] Kim DoY, Lee JMi, Moon SuB, et al. Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus. Nat Biotechnol. 2022;40:94-102.

[75] Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci U S A. 1993;90:8673-8677.

[76] Abaji M, Gorokhova S, Da Silva N, et al. Novel exon-skipping therapeutic approach for the DMD gene based on asymptomatic deletions of exon 49. Genes. 2022;13:1277.

[77] Schellens RTW, Broekman S, Peters T, et al. A protein domain-oriented approach to expand the opportunities of therapeutic exon skipping for -associated retinitis pigmentosa. Mol Ther Nucleic Acids. 2023;32:980-994.

[78] Leier A, Moore M, Liu H, et al. Targeted exon skipping of exon 17 as a therapeutic for neurofibromatosis type I. Mol Ther Nucleic Acids. 2022;28:261-278.

[79] Tabebordbar M, Zhu K, Cheng JKW, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016;351:407-411.

[80] Ran FA, Cong Le, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520:186-191.

[81] Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351:400-403.

[82] Yang Y, Wang L, Bell P, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. 2016;34:334-338.

[83] Behr M, Zhou J, Xu B, Zhang H. In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges. Acta Pharm Sin B. 2021;11:2150-2171.

[84] Yip B. Recent Advances in CRISPR/Cas9 Delivery Strategies. Biomolecules. 2020;10:839.

[85] Marino M, Holt MG. AAV vector-mediated antibody delivery (A-MAD) in the central nervous system. Front Neurol. 2022;13:870799.

[86] Maeder ML, Stefanidakis M, Wilson CJ, et al. Development of a gene-editing approach to restore vision loss in leber congenital amaurosis type 10. Nat Med. 2019;25:229-233.

[87] LeMieux J. Editas medicine pauses trial of CRISPR-Cas9 treatment for blindness disorder. GEN—Genetic Engineering and Biotechnology News

[88] Schümperli D, Pillai RS. The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein. Cell Mol Life Sci. 2004;61:2560-2570.

[89] Wein N, Vetter TA, Vulin A, et al. Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol Ther Methods Clin Dev. 2022;26:279-293.

[90] Aupy P, Zarrouki F, Sandro Q, et al. Long-term efficacy of AAV9-U7snRNA-mediated exon 51 skipping in mdx52 mice. Mol Ther Methods Clin Dev. 2020;17:1037-1047.

[91] Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol. 1998;72:8568-8577.

[92] Clinical trial of gene therapy with dual AAV vectors for retinitis pigmentosa in patients with Usher syndrome type IB. CORDIS|European Commission; 2022.

[93] Kodippili K, Hakim CH, Pan X, et al. Dual AAV gene therapy for Duchenne muscular dystrophy with a 7-kb mini-dystrophin gene in the canine model. Hum Gene Ther. 2018;29:299-311.

[94] Pickar-Oliver A, Gough V, Bohning JD, et al. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. Mol Ther. 2021;29:3243-3257.

[95] Riaz S, Sethna S, Duncan T, et al. Dual AAV-based PCDH15 gene therapy achieves sustained rescue of visual function in a mouse model of usher syndrome 1F. Mol Ther. 2023;31:3490–3501.

[96] Ivanchenko MV, Hathaway DM, Mulhall EM, et al. PCDH15 dual-AAV gene therapy for deafness and blindness in usher syndrome type 1F. Biorxiv. 2023.

[97] Al-Moyed H, Cepeda AP, Jung S, Moser T, Kügler S, Reisinger E. A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice. EMBO Mol Med. 2019;11.

[98] Al-Moyed H, Cepeda AP, Jung S, Moser T, Kügler S, Reisinger E. A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice. EMBO Mol Med. 2019;11:e9396.

[99] Lostal W, Bartoli M, Bourg N, et al. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet. 2010;19:1897-1907.

[100] Potter RA, Griffin DA, Sondergaard PC, et al. Systemic delivery of dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy. Hum Gene Ther. 2018;29:749-762.

[101] Sondergaard PC, Griffin DA, Pozsgai ER, et al. AAV.Dysferlin overlap vectors restore function in dysferlinopathy animal models. Ann Clin Transl Neurol. 2015;2:256-270.

[102] Lai Yi, Yue Y, Liu M, et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol. 2005;23:1435-1439.

[103] Stutika C, Gogol-Döring A, Botschen L, et al. A comprehensive RNA sequencing analysis of the adeno-associated virus (AAV) type 2 transcriptome reveals novel AAV transcripts, splice variants, and derived proteins. J Virol. 2016;90:1278-1289.

[104] Farris KD, Pintel DJ. Improved splicing of adeno-associated viral (AAV) capsid protein-supplying pre-mRNAs leads to increased recombinant AAV vector production. Hum Gene Ther. 2008;19:1421-1427.

[105] McClements ME, MacLaren RE. Adeno-associated virus (AAV) dual vector strategies for gene therapy encoding large transgenes. Yale J Biol Med. 2017;90:611-623.

[106] Trapani I, Colella P, Sommella A, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med. 2014;6:194-211.

[107] Pryadkina M, Lostal W, Bourg N, et al. A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb dysferlin coding sequence. Mol Ther—Methods Clin Dev. 2015;2:15009.

[108] Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther. 2001;4:383-391.

[109] Reisinger E. Dual-AAV delivery of large gene sequences to the inner ear. Hear Res. 2020;394:107857.

[110] Shah NH, Eryilmaz E, Cowburn D, Muir TW. Extein residues play an intimate role in the rate-limiting step of protein trans-splicing. J Am Chem Soc. 2013;135:5839-5847.

[111] Novikova O, Topilina N, Belfort M. Enigmatic distribution, evolution, and function of inteins. J Biol Chem. 2014;289:14490-14497.

[112] Mills KV, Johnson MA, Perler FB. Protein splicing: how inteins escape from precursor proteins. J Biol Chem. 2014;289:14498-14505.

[113] Stevens AJ, Brown ZZ, Shah NH, Sekar G, Cowburn D, Muir TW. Design of a split intein with exceptional protein splicing activity. J Am Chem Soc. 2016;138:2162-2165.

[114] Tornabene P, Trapani I, Minopoli R, et al. Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci Transl Med. 2019;11:eaav4523.

[115] Esposito F, Lyubenova H, Tornabene P, et al. Liver gene therapy with intein-mediated F8 trans-splicing corrects mouse haemophilia A. EMBO Mol Med. 2022;14:e15199.

[116] Ghosh A, Yue Y, Lai Yi, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther. 2008;16:124-130.

[117] Ghosh A, Yue Y, Duan D. Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. Hum Gene Ther. 2011;22:77-83.

[118] Halbert CL, Allen JM, Miller AD. Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat Biotechnol. 2002;20:697-701.

[119] Ferla R, Dell'aquila F, Doria M, et al. Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for usher syndrome type 1B. Mol Ther Methods Clin Dev. 2023;28:396-411.

[120] Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A. 2000;97:6716-6721.

[121] Tharappel AM, Li Z, Li H. Inteins as drug targets and therapeutic tools. Front Mol Biosci. 2022;9:821146.

[122] Riedmayr LM, Hinrichsmeyer KS, Thalhammer SB, et al. mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy. Nat Commun. 2023;14:6578.

[123] Hakim CH, Kumar SRP, Pérez-López DO, et al. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat Commun. 2021;12:6769.

[124] Bliven S, Prlić A. Circular permutation in proteins. PLoS Comput Biol. 2012;8:e1002445.

[125] Schwartz TU, Walczak R, Blobel G. Circular permutation as a tool to reduce surface entropy triggers crystallization of the signal recognition particle receptor beta subunit. Protein Sci. 2004;13:2814-2818.

[126] Uliel S, Fliess A, Unger R. Naturally occurring circular permutations in proteins. Protein Eng. 2001;14:533-542.

[127] Yu Y, Lutz S. Circular permutation: a different way to engineer enzyme structure and function. Trends Biotechnol. 2011;29:18-25.

[128] Kostyuk AI, Demidovich AD, Kotova DA, Belousov VV, Bilan DS. Circularly permuted fluorescent protein-based indicators: history, principles, and classification. Int J Mol Sci. 2019;20:4200.

[129] Luger K, Hommel U, Herold M, Hofsteenge J, Kirschner K. Correct folding of circularly permuted variants of a beta alpha barrel enzyme in vivo. Science. 1989;243:206-210.

[130] Truong J, Hsieh Yu-F, Truong L, Jia G, Hammond MC. Designing fluorescent biosensors using circular permutations of riboswitches. Methods. 2018;143:102-109.

[131] Zhang P, Schachman HK. In vivo formation of allosteric aspartate transcarbamoylase containing circularly permuted catalytic polypeptide chains: implications for protein folding and assembly. Protein Sci. 1996;5:1290-1300.

[132] Viguera AR, Serrano L, Wilmanns M. Different folding transition states may result in the same native structure. Nat Struct Biol. 1996;3:874-880.

[133] Otzen DE, Fersht AR. Folding of circular and permuted chymotrypsin inhibitor 2: retention of the folding nucleus. Biochemistry. 1998;37:8139-8146.

[134] Hennecke J, Sebbel P, Glockshuber R. Random circular permutation of DsbA reveals segments that are essential for protein folding and stability. J Mol Biol. 1999;286:1197-1215.

[135] Parmeggiani F, Huang Po-S. Designing repeat proteins: a modular approach to protein design. Curr Opin Struct Biol. 2017;45:116-123.

[136] Huang Y-M, Nayak S, Bystroff C. Quantitative in vivo solubility and reconstitution of truncated circular permutants of green fluorescent protein. Protein Sci. 2011;20:1775-1780.

[137] Lo W-C, Lee C-C, Lee C-Yu, Lyu P-C. CPDB: a database of circular permutation in proteins. Nucleic Acids Res. 2009;37:D328-D332.

[138] Chen C-C, Huang Yu-W, Huang H-C, Lo W-C, Lyu P-C. SeqCP: a sequence-based algorithm for searching circularly permuted proteins. Comput Struct Biotechnol J. 2023;21:185-201.

[139] Cao L, Coventry B, Goreshnik I, et al. Design of protein-binding proteins from the target structure alone. Nature. 2022;605:551-560.

[140] Huang Po-S, Boyken SE, Baker D. The coming of age of de novo protein design. Nature. 2016;537:320-327.

[141] Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017;8:1603.

[142] Schilling J, Jost C, Ilie IM, et al. Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs. J Biol Chem. 2022;298:101403.

[143] Kudla G, Plech M. Lighting up protein design. eLife. 2022;11:e79310.

[144] Gonzalez Somermeyer L, Fleiss A, Mishin AS, et al. Heterogeneity of the GFP fitness landscape and data-driven protein design. eLife. 2022;11.

[145] Kondrashov DA, Kondrashov FA. Topological features of rugged fitness landscapes in sequence space. Trends Genet. 2015;31:24-33.

[146] He L, Tan P, Zhu L, et al. Circularly permuted LOV2 as a modular photoswitch for optogenetic engineering. Nat Chem Biol. 2021;17:915-923.

[147] Kook YH, Lee H, Lee J, et al. AAV-compatible optogenetic tools for activating endogenous calcium channels in vivo. Mol Brain. 2023;16:73.

[148] Bali B, Lopez De La Morena D, Mittring A, et al. Utility of red-light ultrafast optogenetic stimulation of the auditory pathway. EMBO Mol Med. 2021;13:e13391.

[149] Renaud N, Geng C, Georgievska S, et al. DeepRank: a deep learning framework for data mining 3D protein-protein interfaces. Nat Commun. 2021;12:7068.

[150] Gligorijević V, Renfrew PD, Kosciolek T, et al. Structure-based protein function prediction using graph convolutional networks. Nat Commun. 2021;12:3168.

[151] Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583-589.

[152] Eisenstein M. AI-enhanced protein design makes proteins that have never existed. Nat Biotechnol. 2023;41:303-305.

[153] Kim DE, Jensen DR, Feldman D, et al. De novo design of small beta barrel proteins. Proc Natl Acad Sci U S A. 2023;120:e2207974120.

[154] Au HKE, Isalan M, Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med. 2021;8:809118.

[155] Shen W, Liu S, Ou Li. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: a meta-analysis. Front Immunol. 2022;13:1001263.

[156] Shieh PB, Kuntz NL, Dowling JJ, et al. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial. Lancet Neurol. 2023;22:1125-1139.

[157] uniQure. Huntington's disease. uniQure

[158] Astellas Pharma. Notice regarding impairment loss for products under development. Astellas Pharma.

[159] Lv J, Wang H, Cheng X, et al. AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial. Lancet. 2024;24:S0140-6736(23)02874-X.

[160] Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs. 2019;79:1255-1262.

[161] Kumaran N, Michaelides M, Smith AJ, Ali RR, Bainbridge JWB. Retinal gene therapy. Br Med Bull. 2018;126:13-25.

[162] Chowdhury EA, Meno-Tetang G, Chang HY, et al. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models. Adv Drug Deliv Rev. 2021;170:214-237.

[163] Bijlani S, Pang KaM, Sivanandam V, Singh A, Chatterjee S. The role of recombinant AAV in precise genome editing. Front Genome Ed. 2021;3:799722.

[164] Gaudet D, Stroes ES, Méthot J, et al. Long-term retrospective analysis of gene therapy with Alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis. Hum Gene Ther. 2016;27:916-925.

[165] Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009;374:1597-1605.

[166] Konkle BA, Walsh CE, Escobar MA, et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021;137:763-774.

[167] Leavitt AD, Konkle BA, Stine K, et al. Updated follow-up of the alta study, a phase 1/2 study of Giroctocogene fitelparvovec (SB-525) gene therapy in adults with severe hemophilia a. Blood. 2020;136:12.

[168] Muhuri M, Levy DI, Schulz M, Mccarty D, Gao G. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30:1364-1380.

[169] Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018;29:285-298.

[170] Roca C, Motas S, Marcó S, et al. Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID. Hum Mol Genet. 2017;26:1535-1551.

[171] Mccarty DM, Dirosario J, Gulaid K, Muenzer J, Fu H. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther. 2009;16:1340-1352.

[172] Wilson JM, Flotte TR. Moving forward after two deaths in a gene therapy trial of myotubular myopathy. Hum Gene Ther. 2020;31:695-696.

[173] Chand DH, Zaidman C, Arya K, et al. Thrombotic microangiopathy following Onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2021;231:265-268.

[174] Pfizer. Pfizer's new phase 1b results of gene therapy in ambulatory boys with duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study. Pfizer.

[175] Fitzpatrick Z, Leborgne C, Barbon E, et al. Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction. Mol Ther Methods Clin Dev. 2018;9:119-129.

[176] Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21:704-712.

[177] Klamroth R, Hayes G, Andreeva T, et al. Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A. Hum Gene Ther. 2022;33:432-441.

[178] Martino AT, Herzog RW, Anegon I, Adjali O. Measuring immune responses to recombinant AAV gene transfer. Methods Mol Biol. 2011;807:259-272.

[179] Bertin B, Veron P, Leborgne C, et al. Capsid-specific removal of circulating antibodies to adeno-associated virus vectors. Sci Rep. 2020;10:864.

[180] Weber T. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front Immunol. 2021;12:658399.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.